A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications

Little is known regarding long-term outcomes of patients hospitalized with COVID-19. We conducted a prospective study of 6-month outcomes of hospitalized COVID-19 patients. Patients with new neurological complications during hospitalization who survived were propensity score-matched to COVID-19 surv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the neurological sciences 2021-07, Vol.426, p.117486-117486, Article 117486
Hauptverfasser: Frontera, Jennifer A., Yang, Dixon, Lewis, Ariane, Patel, Palak, Medicherla, Chaitanya, Arena, Vito, Fang, Taolin, Andino, Andres, Snyder, Thomas, Madhavan, Maya, Gratch, Daniel, Fuchs, Benjamin, Dessy, Alexa, Canizares, Melanie, Jauregui, Ruben, Thomas, Betsy, Bauman, Kristie, Olivera, Anlys, Bhagat, Dhristie, Sonson, Michael, Park, George, Stainman, Rebecca, Sunwoo, Brian, Talmasov, Daniel, Tamimi, Michael, Zhu, Yingrong, Rosenthal, Jonathan, Dygert, Levi, Ristic, Milan, Ishii, Haruki, Valdes, Eduard, Omari, Mirza, Gurin, Lindsey, Huang, Joshua, Czeisler, Barry M., Kahn, D. Ethan, Zhou, Ting, Lin, Jessica, Lord, Aaron S., Melmed, Kara, Meropol, Sharon, Troxel, Andrea B., Petkova, Eva, Wisniewski, Thomas, Balcer, Laura, Morrison, Chris, Yaghi, Shadi, Galetta, Steven
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Little is known regarding long-term outcomes of patients hospitalized with COVID-19. We conducted a prospective study of 6-month outcomes of hospitalized COVID-19 patients. Patients with new neurological complications during hospitalization who survived were propensity score-matched to COVID-19 survivors without neurological complications hospitalized during the same period. The primary 6-month outcome was multivariable ordinal analysis of the modified Rankin Scale(mRS) comparing patients with or without neurological complications. Secondary outcomes included: activities of daily living (ADLs;Barthel Index), telephone Montreal Cognitive Assessment and Neuro-QoL batteries for anxiety, depression, fatigue and sleep. Of 606 COVID-19 patients with neurological complications, 395 survived hospitalization and were matched to 395 controls; N = 196 neurological patients and N = 186 controls completed follow-up. Overall, 346/382 (91%) patients had at least one abnormal outcome: 56% had limited ADLs, 50% impaired cognition, 47% could not return to work and 62% scored worse than average on ≥1 Neuro-QoL scale (worse anxiety 46%, sleep 38%, fatigue 36%, and depression 25%). In multivariable analysis, patients with neurological complications had worse 6-month mRS (median 4 vs. 3 among controls, adjusted OR 1.98, 95%CI 1.23–3.48, P = 0.02), worse ADLs (aOR 0.38, 95%CI 0.29–0.74, P = 0.01) and were less likely to return to work than controls (41% versus 64%, P = 0.04). Cognitive and Neuro-QOL metrics were similar between groups. Abnormalities in functional outcomes, ADLs, anxiety, depression and sleep occurred in over 90% of patients 6-months after hospitalization for COVID-19. In multivariable analysis, patients with neurological complications during index hospitalization had significantly worse 6-month functional outcomes than those without. •Abnormalities in functional and cognitive outcomes occurred in >90% of patients 6-months after hospitalization for COVID-19.•Impaired cognition occurred in 50% of COVID-19 patients and 47% were unable to return to work at 6-months.•Patients with neurological complications had significantly worse functional outcomes and were less likely to return to work.
ISSN:0022-510X
1878-5883
1878-5883
DOI:10.1016/j.jns.2021.117486